Direxion Daily S&P Biotech Bear 3X ETF
LABD
11 hedge funds and large institutions have $21.5M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
402% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $6.12M
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.05% more ownership
Funds ownership: 0.13% → 0.18% (+0.05%)
8% less funds holding
Funds holding: 12 → 11 (-1)
9% less capital invested
Capital invested by funds: $23.7M → $21.5M (-$2.21M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.53M |
| 3 |
VF
Virtu Financial
New York
|
+$1.52M |
| 4 |
HF
HRT Financial
New York
|
+$1.06M |
| 5 |
Jane Street
New York
|
+$352K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$2.59M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.54M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.06M |
| 4 |
TSS
Two Sigma Securities
New York
|
-$210K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$170K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $12.4M | +$1.94M | +402 | +19% |
|
|
VF
2
Virtu Financial
New York
| $3.02M | +$1.52M | +314 | +103% |
|
|
3
Citadel Advisors
Miami,
Florida
| $2.18M | +$1.53M | +317 | +244% |
|
|
HF
4
HRT Financial
New York
| $1.26M | +$1.06M | +219 | +548% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $766K | -$2.54M | -527 | -77% |
|
6
Citigroup
New York
| $668K | +$57.9K | +12 | +10% |
|
|
7
Jane Street
New York
| $618K | +$352K | +73 | +135% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $436K | -$2.06M | -426 | -83% |
|
9
UBS Group
Zurich,
Switzerland
| $75K | +$72.4K | +15 | New |
|
10
Simplex Trading
Chicago,
Illinois
| $30K | +$29K | +6 | New |
|
|
CG
11
Cutler Group
San Francisco,
California
| $4K | -$4.83K | -1 | -50% |
|
|
12
SG Americas Securities
New York
| – | -$2.59M | -500 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$210K | -40 | Closed |
|
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$170K | -33 | Closed |
|
LABD Hedge Fund Activity: Q3 2018 in Review
11 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q3 2018, worth a combined $21.5M — down 9.3% from $23.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LABD and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was Morgan Stanley, adding an estimated $1.94M. The largest seller was SG Americas Securities, exiting entirely with an estimated $2.59M sold.
- 11 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q3 2018, down from 12 in Q2 2018.
- Funds reported $21.5M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q3 2018, down 9.3% quarter-over-quarter.
- 2 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q3 2018 and 3 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q3 2018 was Morgan Stanley, an estimated $1.94M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q3 2018 was SG Americas Securities, an estimated $2.59M sold.
Based on aggregated 13F filings for Q3 2018.